-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On June 21, Watson Bio announced that the company’s holding subsidiary Yuxi Watson had recently received the 23-valent pneumococcal polysaccharide vaccine "Drug Supplementary Application Approval Notice" approved by the State Food and Drug Administration, approving Yuxi Watson's 23-valent pneumococcal vaccine For polysaccharide vaccines, the existing packaging form of "prefilled syringes" has been added with "cillin bottle" packaging
Pneumococcal infection is the main causative factor of serious diseases such as meningitis, bacteremia, pneumonia, etc.
The prefilled syringe dosage form of Yuxi Watson's 23-valent pneumococcal polysaccharide vaccine was approved for production and registration on March 22, 2017.